Fidelity SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences > Biotech Values

Recall Merck also tried to get an "improved

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
genisi Member Profile
 
Followed By 31
Posts 5,112
Boards Moderated 0
Alias Born 05/24/06
160x600 placeholder
Heineken has agreed to sell its Mexican packaging business to Crown Holdings for $1.23 billion in cash, allowing the Dutch brewer to tighten its focus on beer.
More Top Equities Stories Of The Day
Apple Investigating Reports of iCloud Vulnerabilities
US Court Dismisses Aluminum Antitrust Cases
J.P. Morgan Working With Law Enforcement on Cyber Attack -- 3rd Update
U.S. Hot Stocks: Hot Stocks to Watch
Ex-LPL Broker Ordered to Pay Nearly $2 Million
U.S. Hot Stocks: Hot Stocks to Watch
Amazon, Twitter Gains Lead Techs Higher
Ukraine Tensions Spur U.S. Stock Futures Downward
genisi   Wednesday, 04/27/11 03:49:51 AM
Re: biomaven0 post# 118902
Post # of 181585 
Recall Merck also tried to get an "improved niacin" by targeting the same receptor with MK-0354, which despite significant decreases in FFAs levels and absence of flushing failed to demonstrate effects on HDL/LDL-Cholesterol and TGs in phase II. Obviously, being a GPR109A receptor agonist isn't all.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist